Published on:
March 6, 2026
Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide, affecting the vast majority of sexually active people at some point in their lives. Whilst many HPV infections clear on their own without causing harm, certain high-risk strains can lead to serious health conditions — most notably cervical cancer, but also cancers of the vulva, vagina, penis, anus, and some types of mouth and throat cancer. The HPV vaccine represents one of the most significant advances in cancer prevention, and the UK's vaccination programme has already delivered remarkable results.
Since the national HPV vaccination programme launched in 2008, the evidence has been overwhelming. A landmark 2021 study published in The Lancet found that cervical cancer rates were reduced by almost 90% in women in their twenties in England who were offered the vaccine at ages 12 to 13. This makes the HPV vaccine not merely a preventive measure but a genuinely transformative public health intervention. If you're considering getting vaccinated or want to understand the programme better, this guide covers everything you need to know about the HPV vaccine and its benefits.
HPV is a group of more than 200 related viruses, of which around 40 types can infect the genital area. These are broadly categorised into low-risk and high-risk types. Low-risk types, such as HPV 6 and 11, are responsible for approximately 90% of genital warts cases — a condition that, whilst not life-threatening, can cause significant distress and discomfort. High-risk types, particularly HPV 16 and 18, are linked to the development of several cancers.
HPV is transmitted through skin-to-skin contact, most commonly during sexual activity. It is so prevalent that most people will contract at least one type of HPV during their lifetime, often without ever knowing. The virus frequently produces no symptoms and resolves naturally within two years. However, when high-risk HPV persists, it can cause cellular changes that may eventually develop into cancer over a period of years or decades.
Persistent infection with high-risk HPV strains can lead to abnormal changes in the cells of the cervix, known as cervical intraepithelial neoplasia (CIN). If left undetected and untreated, these precancerous changes can progress to invasive cervical cancer. HPV types 16 and 18 alone are responsible for around 70% of all cervical cancer cases globally. Beyond the cervix, HPV is implicated in a growing proportion of head and neck cancers, particularly oropharyngeal cancers, making vaccination relevant to both men and women.
The most compelling benefit of the HPV vaccine is its extraordinary effectiveness in preventing cervical cancer. Research published in The Lancet demonstrated that the HPV immunisation programme in England has successfully almost eliminated cervical cancer in women born since September 1995 — those who were offered vaccination at the optimal age of 12 to 13. The study observed substantial reductions not only in cervical cancer incidence but also in grade 3 cervical intraepithelial neoplasia (CIN3), the most severe form of precancerous cervical change.
According to government estimates, the HPV vaccine will prevent up to 90% of cervical cancer cases. This is a staggering figure when one considers that cervical cancer remains the fourth most common cancer in women worldwide. In the UK alone, approximately 3,200 women are diagnosed with cervical cancer each year, and the vaccine has the potential to prevent the overwhelming majority of these cases in future generations.
Whilst cervical cancer prevention is the most well-known benefit, the HPV vaccine offers protection against a broader range of HPV-related cancers. These include cancers of the vulva, vagina, penis, and anus, as well as certain oropharyngeal cancers. As there are currently no national screening programmes for most of these cancers in the UK, vaccination represents the primary line of defence. This is particularly significant for anal and oropharyngeal cancers, which have been rising in incidence in recent decades.
The vaccines used in the UK programme also protect against HPV types 6 and 11, which cause the vast majority of genital warts. Data from the UK Health Security Agency has shown that since the introduction of the vaccination programme, diagnoses of genital warts have fallen dramatically among young people. This benefit extends beyond those directly vaccinated, as reduced circulation of these HPV types within the population provides a degree of herd protection to unvaccinated individuals as well.
One of the most encouraging findings from the UK programme has been its impact across all socioeconomic groups. A study published in The BMJ found that the vaccination programme in England has been associated with substantial reductions in cervical neoplasia not only overall but across all levels of socioeconomic deprivation. Since cervical cancer disproportionately affects women in more deprived communities, the universal school-based vaccination programme is actively helping to narrow the health equality gap — a benefit that extends well beyond individual protection.
The UK's HPV vaccination programme began in September 2008, initially targeting girls aged 12 to 13 with a catch-up programme for older girls up to age 18. The original programme used the bivalent vaccine Cervarix, which protected against HPV types 16 and 18. In 2012, the programme switched to the quadrivalent vaccine Gardasil, adding protection against HPV types 6 and 11. A pivotal change came in 2019 when the programme was extended to include boys of the same age, recognising that HPV-related cancers affect all genders.
Since 2022, the programme has used the nonavalent vaccine Gardasil 9, which protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). This broader coverage is expected to lead to up to 90% reductions in cancers caused by these high-risk types by 2040. Another significant simplification came when the schedule was reduced from two doses to a single dose, based on evidence that one dose provides sufficient long-lasting protection.
Under the current programme, all children in England are offered the HPV vaccine in Year 8 (aged 12 to 13) as part of the routine school-based immunisation schedule. The vaccine is delivered in schools by School Age Immunisation Service teams, making it easily accessible. Children who miss their school-based vaccination can catch up through their GP or local immunisation services until their 25th birthday.
Additionally, men who have sex with men (MSM) up to age 45 are eligible for free HPV vaccination through sexual health clinics and some GP surgeries, reflecting the higher risk of HPV-related cancers in this group. People living with HIV are also offered vaccination due to their increased vulnerability to HPV-related complications.
Despite the programme's success, uptake has become a growing concern. Recent government data indicates that over a quarter of eligible pupils are missing out on the HPV vaccine, a decline that has been partly attributed to disruption caused by the COVID-19 pandemic, as well as growing vaccine hesitancy. The UK Health Security Agency has emphasised that maintaining high vaccination coverage is essential to sustaining the programme's cancer-preventing benefits and ensuring herd protection across the population.
It is crucial to understand that the HPV vaccine and cervical screening work hand in hand. Whilst the vaccine provides powerful protection against the most dangerous HPV types, it does not protect against all strains that can cause cervical cancer. For this reason, vaccinated women should still attend for cervical screening (smear tests) when invited. Cervical screening can detect HPV infection and abnormal cell changes before they develop into cancer, allowing for early intervention.
In England, women and people with a cervix are invited for cervical screening from age 25. The test now primarily checks for the presence of high-risk HPV, with cell analysis carried out only if HPV is detected. This HPV-first approach has improved the sensitivity of screening and means that abnormalities are caught earlier. Together, vaccination and screening form a comprehensive strategy that could see cervical cancer virtually eliminated in the UK within the coming decades.
It is worth noting that there are currently no equivalent screening programmes for other HPV-related cancers, such as those affecting the anus, penis, or throat. This underscores the importance of vaccination as the primary preventive tool for these conditions, and it highlights why ensuring broad vaccine coverage — including among boys and young men — is so vital.
The HPV vaccine has been extensively studied and has an excellent safety profile. It has been administered to hundreds of millions of people worldwide since its introduction. The most common side effects are mild and temporary, including soreness at the injection site, headache, and slight fatigue. Serious adverse reactions are extremely rare. The World Health Organization, the European Medicines Agency, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) all continue to affirm the vaccine's safety.
The HPV vaccine is most effective when given before exposure to the virus, which is why the programme targets young adolescents before they become sexually active. However, the vaccine can still offer significant benefits to older individuals who have not been exposed to all the HPV types covered by the vaccine. Adults who were not vaccinated during adolescence may wish to discuss private vaccination with their GP or a specialist clinic, particularly if they have risk factors for HPV-related conditions.
A common concern raised by some parents is whether HPV vaccination might encourage earlier or riskier sexual behaviour. Multiple large-scale studies have consistently found no evidence to support this claim. Vaccinated young people are no more likely to engage in sexual activity at an earlier age or to have more sexual partners than their unvaccinated peers. The vaccine is simply a cancer prevention tool, much like any other childhood immunisation.
The UK is widely regarded as a global leader in HPV vaccination, and the programme's impact continues to grow. With the introduction of the nonavalent Gardasil 9 vaccine and the move to a single-dose schedule, the programme is becoming both more protective and more efficient. Modelling studies suggest that if high vaccination coverage is maintained, the UK could see cervical cancer rates fall to fewer than one case per 100,000 women — effectively meeting the World Health Organization's threshold for elimination as a public health problem.
However, realising this ambition depends on addressing the recent decline in uptake. Public health authorities are working to improve access through catch-up campaigns and community outreach, whilst countering misinformation that has contributed to vaccine hesitancy. Parents and young people are encouraged to take advantage of this life-saving vaccination, whether through the school programme or through catch-up opportunities available at GP surgeries and clinics.
Beyond cervical cancer, ongoing research is exploring whether the HPV vaccine could have therapeutic applications — potentially helping to treat existing HPV infections or precancerous lesions. Whilst this remains an area of active investigation, the preventive benefits already demonstrated by the vaccine are nothing short of extraordinary. For anyone who has missed out on the school-based programme, private HPV vaccination is available and remains one of the most impactful steps you can take to protect your long-term health.
All children in Year 8 (aged 12 to 13) are offered the HPV vaccine through the school-based programme. Those who miss their vaccination can catch up until age 25. Men who have sex with men (MSM) up to age 45 and people living with HIV are also eligible for free vaccination through sexual health services. Adults outside these groups can access the vaccine privately.
The HPV vaccine is highly effective. Research has shown it can prevent up to 90% of cervical cancer cases. A major study published in The Lancet found that cervical cancer was almost eliminated in women who received the vaccine at ages 12 to 13 in England, with an approximately 87% reduction in cancer rates among this group.
Yes, absolutely. Whilst the HPV vaccine provides excellent protection, it does not cover all HPV types that can cause cervical cancer. Regular cervical screening remains essential for early detection of any abnormal changes. Women and people with a cervix should attend their smear test appointments when invited, starting from age 25.
The HPV vaccine has an extensive safety record, having been administered to hundreds of millions of people globally. Side effects are typically mild and short-lived, such as soreness at the injection site or a slight headache. Serious reactions are extremely rare. The vaccine's safety is continuously monitored by regulatory agencies in the UK and around the world.
Yes. Individuals who missed the school-based programme can receive the vaccine free on the NHS up to their 25th birthday. Those over 25 who wish to be vaccinated can access the HPV vaccine through private healthcare providers. Vaccination can still offer benefits to adults who have not been exposed to all the HPV types covered by the vaccine.
The information provided in this article is for educational purposes only and is based on NHS recommendations. It is not a substitute for professional medical advice. Always consult your doctor or a qualified healthcare provider for advice on medical conditions or treatments.
Our medical centre is at 36 Spital Square, E1 6DY, City of London.
